Brett Grieb, MD
Hematology & Oncology · Lincoln, NENPI 1740714419
Payments from drug & device makers
Across 76 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$194
- AstraZeneca$108
- E.r. Squibb & Sons, L.L.C.$103
- Bristol Myers Squibb$94
- Novartis$86
- Merck$76
- plus $707 from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $194 |
| AstraZeneca | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 6 | $103 |
| Bristol Myers Squibb | 6 | $94 |
| Novartis | 5 | $86 |
| Merck | 4 | $76 |
| Johnson & Johnson | 3 | $74 |
| Sanofi | 3 | $67 |
| Eisai Inc. | 3 | $60 |
| Genmab U.S., Inc. | 3 | $55 |
| AbbVie | 2 | $53 |
| Bayer | 2 | $38 |
| GSK | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Immunogen, Inc. | 1 | $19 |
| Organon | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| CTI Biopharma Corp. | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
| Medtronic | 1 | $14 |
| Gilead | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
How this compares
$1,368 in reported general payments places this provider in the 20th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Lincoln
- Kailash MosalpuriaLincoln$4.2M
- Madhu MidathadaLincoln$1.1M
- Mark HutchinsLincoln$1.1M
- Eric AveryLincoln$1.1M
- Steven DunderLincoln$612K
- Stacey KnoxLincoln$573K
- Alan BergLincoln$396K
- Joni TilfordLincoln$181K
- Nathan GreenLincoln$136K
- Scott McHamLincoln$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.